BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Stock Earnings Estimates

NASDAQ:BBOT • US1079241022

11.25 USD
-0.17 (-1.49%)
At close: Feb 13, 2026
11.25 USD
0 (0%)
After Hours: 2/13/2026, 8:00:01 PM

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027
Revenue
YoY % growth
BBOT revenue by date.BBOT revenue by date.
N/AN/AN/A
EBITDA
YoY % growth
BBOT ebitda by date.BBOT ebitda by date.
N/AN/AN/AN/AN/AN/A
-41.77%
N/A
-10.22%
EBIT
YoY % growth
BBOT ebit by date.BBOT ebit by date.
-43.4K-3.5K
91.94%
-41.7K
-1,091.43%
-584.4K
-1,301.44%
N/A
-26,176.37%
N/A
-38.93%
N/A
-19.44%
Operating Margin
BBOT operating margin by date.BBOT operating margin by date.
N/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
BBOT eps by date.BBOT eps by date.
N/AN/AN/AN/AN/AN/A
32.67%
N/A
-9.30%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth
-0.53-0.54-0.57-0.61
41.01%
-0.61
-15.44%
-0.56
-3.65%
-0.52
8.68%
-0.54
11.86%
-0.55
10.22%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
-50.867M-52.285M-54.376M-56.508MN/AN/AN/AN/AN/A
EBIT
Q2Q % growth
-48.254M
-21,984.02%
-46.83M
-1,834.18%
-49.27M
-4,291.70%
-51.637M
-64.77%
-52.822M
-9.47%
N/AN/AN/AN/A

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2025
Q2Q % growth
-1.03 -0.40-0.63-159.04%
BBOT Yearly EPS VS EstimatesBBOT Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -1 -2 -3
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 0% 3.56% -59.62%
RevenueN/A N/A N/A N/A